Showing 1681-1690 of 2657 results for "".
- Heru Expands Wearable Platform with Launch of Dark Adaptationhttps://modernod.com/news/heru-expands-wearable-platform-with-launch-of-dark-adaptation-establishing-market-leading-amd-portfolio/2481090/Heru announced the launch of dark adaptation, the newest modality added to its wearable health and wellness platform’s vision screening line-up. Dark adaptation measures the eye’s ability to adjust from light to dark environments. Impaired dark adaptation may be one of the
- Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the UShttps://modernod.com/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us/2481003/Dr. Reddy’s Laboratories, along with its subsidiaries, announced it has entered into a licensing agreement with Princeton, New Jersey-based Slayback Pharma to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify
- OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Diseasehttps://modernod.com/news/olix-pharmaceuticals-subsidiary-mcurex-announces-mrna-technology-collaboration-with-toolgen-for-rare-eye-disease/2480920/OliX Pharmaceuticals, a\ developer of RNAi therapeutics, announced that the company’s subsidiary, mCureX Therapeutics, has recently signed a contract for joint research with ToolGen to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technol
- SIFI Announces EMA Validation of its Marketing Authorization Application for Akantior for the Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-announces-ema-validation-of-its-marketing-authorization-application-for-akantior-for-the-treatment-of-acanthamoeba-keratitis/2480899/SIFI announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for Akantior (polihexanide) for the treatment of acanthamoeba keratitis (AK). Today's announcement follows the company’s announcement in October 2
- Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technologyhttps://modernod.com/news/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatility-of-suprachoroidal-delivery-technology/2480845/Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalm
- Innovega Grants Commercial License of its Next-Generation Display Eyewear to Global Supplierhttps://modernod.com/news/innovega-grants-commercial-license-of-its-next-generation-display-eyewear-to-global-supplier/2480728/Innovega finalized a definitive licensing agreement with one of the world's leading providers of assistive technology for the visually impaired, including the legally blind. This is the first commercial licensing agreement for Innovega’s next-generation display eyewear
- Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conferencehttps://modernod.com/news/clearside-biomedicals-suprachoroidal-injection-platform-featured-at-the-angiogenesis-exudation-and-degeneration-2022-virtual-conference/2480642/Clearside Biomedical announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12,
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt
- Kubota Vision Initiates PBOS Prospective Study in Patientshttps://modernod.com/news/kubota-vision-initiates-pbos-prospective-study-in-patients/2480577/Kubota Vision announced that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using the company's Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT) device. The study is being led by S
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin